Clinical trial NCT03981003: Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
Official title: Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Multiple Sclerosis
Keywords: Neurofilament-light chain
Glial fibrillary Acidic Protein (GFAP)
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
Collaborators: name: Hospices Civils de Lyon
First posted: 2019-06-10
Enrollment: 1150
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population is composed of consecutive patients over 15 years of age, of both sexes, recruited during consultations for a CIS, RRMS or progressive MS at the Neurology department of 30 OFSEP centres and of Nîmes and Nantes University Hospitals. The patients recruited will have an EDSS score comprised between 0 - 7.0.

Brief summary: The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease.

In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.


Eligibility criteria: Inclusion Criteria:

* The patient has been correctly informed.
* The patient must have given their informed and signed consent.
* The patient must be insured or beneficiary of a health insurance plan.
* The patient is at least (≥)15 years old.
* The patient has MS according to diagnosis criteria (Thompson et al. 2017) and:

  * Participates to the OFSEP-HD cohort (ancillary study);
  * Has a Expanded Disability Status Scale score comprised between 0 - 7.0;
  * With or without Disease Modifying Drug;
  * For Work Package 3: patients enrolled in any OFSEP-HD centre that meet landmark criteria for an active MS (relapse, or Expanded Disability Status Scale progression, or active MRI) during follow-up;
  * For Work Package 4: patients with a stable disease enrolled in OFSEP-HD study in Nîmes or Nantes University Hospitals.

Exclusion Criteria:

* Within the past three months, the patient has participated in another interventional study that may interfere with the results or conclusions of this study.
* The patient is in an exclusion period determined by a previous study.
* The patient is under judicial protection.
* The patient refuses to sign the consent.
* It is impossible to correctly inform the patient (inability to understand the study, language problem).
* The patient is pregnant or breast-feeding.
* The patient is under 15 years old.
* Inability to answer questionnaires.
* Clinically isolated syndrome (CIS) that does not meet the criteria of MS.
* Radiologically isolated syndrome (RIS).
* Patient with Neuromyelitis optica spectrum disorder.

Primary outcomes:
measure: Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
timeFrame: Inclusion
measure: GFAP level in patients with evolving disease compared to those with stable disease
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
timeFrame: 6 months
measure: GFAP level in patients with evolving disease compared to those with stable disease
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
timeFrame: 12 months
measure: GFAP level in patients with evolving disease compared to those with stable disease
timeFrame: 12 months
measure: Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
timeFrame: 18 months
measure: GFAP level in patients with evolving disease compared to those with stable disease
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
timeFrame: 2 years
measure: GFAP level in patients with evolving disease compared to those with stable disease
timeFrame: 3 years
measure: GFAP level in patients with evolving disease compared to those with stable disease
timeFrame: 4 years
measure: GFAP level in patients with evolving disease compared to those with stable disease
timeFrame: 5 years
measure: GFAP level in patients with evolving disease compared to those with stable disease
timeFrame: 6 years
Secondary outcomes:
measure: Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
timeFrame: Inclusion
measure: GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
timeFrame: 6 months
measure: GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
timeFrame: 3 year
measure: Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
timeFrame: 4 year
measure: Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
timeFrame: 5 year
measure: Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
timeFrame: 6 year
measure: GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
timeFrame: 18 months
measure: GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
timeFrame: 2 years
measure: GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
timeFrame: 2 years
measure: Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
timeFrame: Inclusion
measure: GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
timeFrame: 6 months
measure: GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
timeFrame: 1 year
measure: GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
timeFrame: 18 months
measure: GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
timeFrame: 2 years
measure: GFAP level in patients with relapse compared to stable patients
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in patients with relapse compared to stable patients
timeFrame: 6 months
measure: GFAP level in patients with relapse compared to stable patients
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in patients with relapse compared to stable patients
timeFrame: 1 year
measure: GFAP level in patients with relapse compared to stable patients
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in patients with relapse compared to stable patients
timeFrame: 18 months
measure: GFAP level in patients with relapse compared to stable patients
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in patients with relapse compared to stable patients
timeFrame: 2 years
measure: GFAP level in patients with relapse compared to stable patients
timeFrame: 2 years
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
timeFrame: Inclusion
measure: GFAP level in patients with isolated MRI activity compared to stable patients
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
timeFrame: 6 months
measure: GFAP level in patients with isolated MRI activity compared to stable patients
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
timeFrame: 1 year
measure: Serum GFAP level in patients with isolated MRI activity compared to stable patients
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
timeFrame: 18 months
measure: Serum GFAP level in patients with isolated MRI activity compared to stable patients
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
timeFrame: 2 years
measure: Serum GFAP level in patients with isolated MRI activity compared to stable patients
timeFrame: 2 years
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
timeFrame: Inclusion
measure: Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
timeFrame: 6 months
measure: Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
timeFrame: 1 year
measure: Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
timeFrame: 18 months
measure: Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
timeFrame: 2 year
measure: Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
timeFrame: 2 year
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
timeFrame: Inclusion
measure: Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
timeFrame: 6 months
measure: Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
timeFrame: 1 year
measure: Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
timeFrame: 18 months
measure: Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
timeFrame: 2 years
measure: Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
timeFrame: 2 years
measure: Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
timeFrame: Inclusion
measure: Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
timeFrame: 6 months
measure: Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
timeFrame: 1 year
measure: Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
timeFrame: 18 months
measure: Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
timeFrame: 2 years
measure: Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
timeFrame: 2 years
measure: Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
timeFrame: Inclusion
measure: Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
timeFrame: 6 months
measure: Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
timeFrame: 1 year
measure: Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
timeFrame: 18 months
measure: Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
timeFrame: 2 years
measure: Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
timeFrame: 2 years
measure: Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
timeFrame: Inclusion
measure: Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
timeFrame: 6 months
measure: Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
timeFrame: 1 year
measure: Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
timeFrame: 18 months
measure: Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
timeFrame: 2 years
measure: Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
timeFrame: 2 years
measure: Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)
timeFrame: Inclusion
measure: Serum GFAP level in patients with disease activity (relapse or MRI activity)
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in patients with disease activity (relapse, or MRI activity)
timeFrame: 6 months
measure: Serum GFAP level in patients with disease activity (relapse, or MRI activity)
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)
timeFrame: 1 year
measure: Serum GFAP level in patients with disease activity (relapse or MRI activity)
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)
timeFrame: 18 months
measure: Serum GFAP level in patients with disease activity (relapse or MRI activity)
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)
timeFrame: 2 years
measure: Serum GFAP level in patients with disease activity (relapse or MRI activity)
timeFrame: 2 years
measure: Serum Neurofilament Light Chain level in patients with relapses
timeFrame: Inclusion
measure: Serum GFAP level in patients with relapses
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in patients with relapses
timeFrame: 6 months
measure: Serum GFAP level in patients with relapses
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in patients with relapses
timeFrame: 1 year
measure: Serum GFAP level in patients with relapses
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in patients with relapses
timeFrame: 18 months
measure: Serum GFAP level in patients with relapses
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in patients with relapses
timeFrame: 2 years
measure: Serum GFAP level in patients with relapses
timeFrame: 2 years
measure: Serum Neurofilament Light Chain level in patients with MRI activity
timeFrame: Inclusion
measure: Serum GFAP level in patients with MRI activity
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in patients with MRI activity
timeFrame: 6 months
measure: Serum GFAP level in patients with MRI activity
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in patients with MRI activity
timeFrame: 1 year
measure: Serum GFAP level in patients with MRI activity
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in patients with MRI activity
timeFrame: 18 months
measure: Serum GFAP level in patients with MRI activity
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in patients with MRI activity
timeFrame: 2 years
measure: Serum GFAP level in patients with MRI activity
timeFrame: 2 years
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
timeFrame: Inclusion
measure: Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
timeFrame: 6 months
measure: Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
timeFrame: 1 year
measure: Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
timeFrame: 18 months
measure: Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
timeFrame: 2 years
measure: Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
timeFrame: 2 years
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
timeFrame: Inclusion
measure: Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
timeFrame: 6 months
measure: Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
timeFrame: 6 months
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
timeFrame: 1 year
measure: Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
timeFrame: 1 year
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
timeFrame: 18 months
measure: Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
timeFrame: 18 months
measure: Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
timeFrame: 2 years
measure: Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
timeFrame: 2 years
measure: Level of disability
timeFrame: Inclusion
measure: Level of disability
timeFrame: Relapse (measured up to 2 years)
measure: Severity of multiple sclerosis
timeFrame: EDSS progression (measured up to 2 years)
measure: Severity of multiple sclerosis
timeFrame: Active MRI (measured up to 2 years)
measure: Generic health status
timeFrame: Inclusion
measure: Generic health status
timeFrame: Relapse (measured up to 2 years)
measure: Generic health status
timeFrame: EDSS progression (measured up to 2 years)
measure: Generic health status
timeFrame: active MRI (measured up to 2 years)
measure: Use of Disease Modifying Drugs
timeFrame: Inclusion
measure: Use of Disease Modifying Drugs
timeFrame: 6 monrths
measure: Use of Disease Modifying Drugs
timeFrame: 1 year
measure: Use of Disease Modifying Drugs
timeFrame: 18 months
measure: Use of Disease Modifying Drugs
timeFrame: 2 years
measure: Serum Neurofilament Light Chain in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients
timeFrame: Inclusion
measure: Serum GFAP in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients
timeFrame: Month 6
measure: Serum GFAP in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients
timeFrame: Month 6
measure: Serum Neurofilament Light Chain in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion
timeFrame: Inclusion
measure: Serum GFAP in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion
timeFrame: Inclusion
measure: Serum Neurofilament Light Chain in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion
timeFrame: Month 6
measure: Serum GFAP in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion
timeFrame: Month 6
measure: Create biobank
timeFrame: Inclusion
measure: Create biobank
timeFrame: 6 months
measure: Create biobank
timeFrame: 1 year
measure: Create biobank
timeFrame: 18 months
measure: Create biobank
timeFrame: 2 years
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU d'Amiens
city: Besançon
country: France
facility: CHU de Besancon
city: Bordeaux
country: France
facility: CHU de Bordeaux
city: Caen
country: France
facility: CHU de Caen
city: Clermont-Ferrand
country: France
facility: CHU de Clermont Ferrand
city: Créteil
country: France
facility: Hopital Henri Mondor
city: Dijon
country: France
facility: CHU de Dijon
city: Grenoble
country: France
facility: CHU de Grenoble
city: Lille
country: France
facility: CHU de Lille
city: Limoges
country: France
facility: CHU de Limoges
city: Lyon
country: France
facility: CHU de Lyon
city: Marseille
country: France
facility: Hopital Timone
city: Montpellier
country: France
facility: CHU de Montpellier
city: Nancy
country: France
facility: CHU de Nancy
city: Nice
country: France
facility: CHU de Nice
city: Nîmes
country: France
facility: CHU de Nimes
city: Paris
country: France
facility: Fondation Rothschild
city: Paris
country: France
facility: Hopital Pitie Salpetriere
city: Paris
country: France
facility: Hopital Saint Antoine
city: Poissy
country: France
facility: CH de Poissy
city: Potiers
country: France
facility: CHU de Potiers
city: Rennes
country: France
facility: CHU de Rennes
city: Rouen
country: France
facility: CHU de Rouen
city: Saint-Étienne
country: France
facility: CHU de Saint Etienne
city: Strasbourg
country: France
facility: CHU de Strasbourg
city: Toulouse
country: France
facility: CHU de Toulouse
city: Tours
country: France
facility: CHU de Tours
city: Fort-de-France
country: Martinique
facility: CHU de Martinique
Study officials:
affiliation: CHU Nimes
name: Eric Thouvenot
role: PRINCIPAL_INVESTIGATOR
References: